Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Craig Hall

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
AJR. American Journal of Roentgenology|June 23, 2004
Percutaneous CT-guided radiofrequency ablation of renal neoplasms: factors influencing successRonald J Zagoria, Ashley D Hawkins, Peter E Clark, et al.
Cancer|August 5, 2006
Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancerLester S Borden, Peter E Clark, James Lovato, et al.
Carcinogenesis|December 21, 2005
DNA damage levels in prostate cancer cases and controlsKristin L Lockett, M Craig Hall, Peter E Clark, et al.
The Journal of Urology|November 13, 2007
Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 updateM Craig Hall, Sam S Chang, Guido Dalbagni, et al.
Carcinogenesis|January 5, 2008
Interactions of cytokine gene polymorphisms in prostate cancer riskJovanny Zabaleta, Hui-Yi Lin, Rosa A Sierra, et al.
Urology|April 3, 2003
Analysis of G/A polymorphism in the androgen response element I of the PSA gene and its interactions with the androgen receptor polymorphismsAnuradha Rao, Bao-L i Chang, Gregory Hawkins, et al.
Carcinogenesis|May 29, 2009
Cytokine genetic polymorphisms and prostate cancer aggressivenessJovanny Zabaleta, L Joseph Su, Hui-Yi Lin, et al.
Urology|June 9, 2004
Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinomaPeter E Clark, M Craig Hall, Antonius Miller, et al.
Cancer Research|September 3, 2004
The ADPRT V762A genetic variant contributes to prostate cancer susceptibility and deficient enzyme functionKristin L Lockett, M Craig Hall, Jianfeng Xu, et al.
Cancer|November 24, 2004
Society of Urologic Oncology position statement: redefining the management of hormone-refractory prostate carcinomaSam S Chang, Mitchell C Benson, Steven C Campbell, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
AJR. American Journal of Roentgenology|June 23, 2004
Percutaneous CT-guided radiofrequency ablation of renal neoplasms: factors influencing successRonald J Zagoria, Ashley D Hawkins, Peter E Clark, et al.
Cancer|August 5, 2006
Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancerLester S Borden, Peter E Clark, James Lovato, et al.
Carcinogenesis|December 21, 2005
DNA damage levels in prostate cancer cases and controlsKristin L Lockett, M Craig Hall, Peter E Clark, et al.
The Journal of Urology|November 13, 2007
Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 updateM Craig Hall, Sam S Chang, Guido Dalbagni, et al.
Carcinogenesis|January 5, 2008
Interactions of cytokine gene polymorphisms in prostate cancer riskJovanny Zabaleta, Hui-Yi Lin, Rosa A Sierra, et al.
Urology|April 3, 2003
Analysis of G/A polymorphism in the androgen response element I of the PSA gene and its interactions with the androgen receptor polymorphismsAnuradha Rao, Bao-L i Chang, Gregory Hawkins, et al.
Carcinogenesis|May 29, 2009
Cytokine genetic polymorphisms and prostate cancer aggressivenessJovanny Zabaleta, L Joseph Su, Hui-Yi Lin, et al.
Urology|June 9, 2004
Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinomaPeter E Clark, M Craig Hall, Antonius Miller, et al.
Cancer Research|September 3, 2004
The ADPRT V762A genetic variant contributes to prostate cancer susceptibility and deficient enzyme functionKristin L Lockett, M Craig Hall, Jianfeng Xu, et al.
Cancer|November 24, 2004
Society of Urologic Oncology position statement: redefining the management of hormone-refractory prostate carcinomaSam S Chang, Mitchell C Benson, Steven C Campbell, et al.
Pageof 4